Oncogenic potential of CK2α and its regulatory role in EGF-induced HDAC2 expression in human liver cancer

FEBS Journal

Volumn 281, Issue 3, 2014, Pages 851-861

  Kim, Hyung S ^a   Chang, Young G ^a   Bae, Hyun J ^a   Eun, Jung W ^a   Shen, Qingyu ^a   Park, Se J ^a   Shin, Woo C ^a   Lee, Eun K ^a   Park, Soha ^b   Ahn, Young M ^c   Park, Won S ^a   Lee, Jung Y ^a   Nam, Suk W ^a  

^a The Catholic University of Korea   (South Korea)

^b Yonsei University   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

Akt; CK2 ; EGF; HDAC2; Liver cancer

Indexed keywords

CASEIN KINASE II; CYCLIN B; EPIDERMAL GROWTH FACTOR; HISTONE DEACETYLASE 2; PROTEIN CDC25C; PROTEIN CK2ALPHA; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CELL CYCLE REGULATION; CELL DISRUPTION; COHORT ANALYSIS; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; TRANSCRIPTION INITIATION; UPREGULATION;

CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CASEIN KINASE II; CELL LINE, TUMOR; CELL PROLIFERATION; COHORT STUDIES; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 2; HUMANS; LIVER; LIVER NEOPLASMS; MUTANT PROTEINS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84897860012     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12652     Document Type: Article

References (22)

1. Glozak MA & Seto E (2007) Histone deacetylases and cancer. Oncogene 26, 5420-5432.
2. Weichert W (2009) HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280, 168-176.
3. Witt O, Deubzer HE, Milde T & Oehme I (2009) HDAC family: what are the cancer relevant targets? Cancer Lett 277, 8-21.
4. Gallinari P, Di Marco S, Jones P, Pallaoro M & Steinkuhler C (2007) HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17, 195-211.
5. Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park WS, Lee JY, et al. (2011) Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS ONE 6, e28103.
6. Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369, 1-15.
7. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, Pinna LA & Ruzzene M (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12, 668-677.
8. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, et al. (2001) A phosphatase associated with metastasis of colorectal cancer. Science 294, 1343-1346.
9. St-Denis NA & Litchfield DW (2009) Protein kinase CK2 in health and disease: from birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci 66, 1817-1829.
10. Eom GH, Cho YK, Ko JH, Shin S, Choe N, Kim Y, Joung H, Kim HS, Nam KI, Kee HJ, et al. (2011) Casein kinase-2a1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart. Circulation 123, 2392-2403.
11. Pluemsampant S, Safronova OS, Nakahama K & Morita I (2008) Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors. Int J Cancer 122, 333-341.
12. Nam SW, Park JY, Ramasamy A, Shevade S, Islam A, Long PM, Park CK, Park SE, Kim SY, Lee SH, et al. (2005) Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 42, 809-818.
13. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, et al. (2010) CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70, 10288-10298.
14. Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park H, Lee JY, et al. (2012) HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem 113, 2167-2177.
15. Kim JK, Noh JH, Eun JW, Jung KH, Bae HJ, Shen Q, Kim MG, Chang YG, Kim SJ, Park WS, et al. (2013) Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer. Mol Cancer Res 11, 62-73.
16. Arrant AE, Jemal H & Kuhn CM (2013) Adolescent male rats are less sensitive than adults to the anxiogenic and serotonin-releasing effects of fenfluramine. Neuropharmacology 65, 213-222.
17. Noh JH, Chang YG, Kim MG, Jung KH, Kim JK, Bae HJ, Eun JW, Shen Q, Kim SJ, Kwon SH, et al. (2013) MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett 335, 455-462.
18. Guo C, Yu S, Davis AT, Wang H, Green JE & Ahmed K (2001) A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells. J Biol Chem 276, 5992-5999.
19. Sayed M, Pelech S, Wong C, Marotta A & Salh B (2001) Protein kinase CK2 is involved in G2 arrest and apoptosis following spindle damage in epithelial cells. Oncogene 20, 6994-7005.
20. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A & Ponte JF (2003) Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983, 84-100.
21. Sun JM, Chen HY, Moniwa M, Litchfield DW, Seto E & Davie JR (2002) The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2. J Biol Chem 277, 35783-35786.
22. Niyazi M, Niyazi I & Belka C (2007) Counting colonies of clonogenic assays by using densitometric software. Radiat Oncol 2, 4.